Delcath Systems (NASDAQ:DCTH) Stock Moved Up to Strong-Buy by Zacks Research

Delcath Systems (NASDAQ:DCTH) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

DCTH has been the topic of several other research reports. Weiss Ratings raised shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Thursday. BTIG Research boosted their target price on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, HC Wainwright raised their price target on shares of Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Buy” and an average price target of $29.33.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $21.38 on Wednesday. The stock’s fifty day moving average is $15.80 and its two-hundred day moving average is $12.65. The firm has a market capitalization of $743.81 million, a P/E ratio of 133.62 and a beta of 0.62. Delcath Systems has a fifty-two week low of $8.12 and a fifty-two week high of $22.51.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. The business had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million. As a group, sell-side analysts forecast that Delcath Systems will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of hedge funds have recently made changes to their positions in DCTH. Royal Bank of Canada raised its position in Delcath Systems by 14.8% in the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after purchasing an additional 2,364 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Delcath Systems during the second quarter worth $48,000. IFP Advisors Inc acquired a new position in Delcath Systems during the second quarter worth $52,000. Alps Advisors Inc. boosted its position in shares of Delcath Systems by 30.3% during the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after buying an additional 10,600 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Delcath Systems by 54.0% during the first quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock worth $536,000 after buying an additional 20,249 shares during the period. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Trending Headlines about Delcath Systems

Here are a few of the latest headlines about DCTH:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analysts’ expected loss of $0.09, and revenue of $35.1 million, above the $26.0 million estimate. The earnings surprise has been cited alongside a recent advance in the shares. Article: Delcath Systems stock price up on better-than-expected earnings
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 price target while lifting its FY2026 EPS estimate to $0.13 from a projected loss of $0.17 and its FY2027 estimate to $0.33 from $0.12. The higher forecasts imply improved expectations for profitability. Article: HC Wainwright earnings estimate revisions
• Positive Sentiment: A Zacks report says the analyst consensus price target suggests 27.7% upside and notes that upward earnings-estimate revisions could support the stock. It cautions, however, that price targets alone have limited predictive value. Article: Wall Street analysts see potential upside

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.